Berger Montague investigates Hims and Hers after stock drops 26% following Novo Nordisk's termination of GLP-1 drug partnership.

The breakup between Hims & Hers and Novo Nordisk has hit HIMS stock hard with a 35% crash. Click here for a full investment ...

Novo Nordisk has ended its partnership with Hims & Hers, citing concerns over the telehealth company’s promotion and sale of the drugmaker’s compounded versions of Wegovy. The drugmaker alleged that ...

Novo Nordisk A/S scrapped a partnership with Hims & Hers Health Inc. after less than two months, saying the US company is ...

Hims & Hers delivered record Q1 results and expanded into Europe with the Zava acquisition. Click here to see why HIMS stock is a Hold.

Novo Nordisk, the company behind blockbuster weight-loss drugs like Ozempic and Wegovy, had a deal with Hims & Hers that ...

Shares in two companies slide as Danish drugmaker accuses US telehealth group of deceptively marketing replica treatments ...

Hims & Hers (NYSE: HIMS) stock, a prominent player in the booming telehealth sector, has undeniably captured significant ...

After scooping up $40,000 worth of Hims & Hers stock, you would hold approximately ... citing concerns about a slowdown in U.S. growth and uncertainties surrounding the blockbuster Zava deal.

Many companies have failed to disrupt the complicated U.S. healthcare market. Hims & Hers (NYSE: HIMS) may finally be succeeding in cracking the code. The online telehealth platform focuses on ...